As included in the partnership between Neurolov and mobiNODE, the users can expect a robust DePIN infrastructure driven by the AI technology.As included in the partnership between Neurolov and mobiNODE, the users can expect a robust DePIN infrastructure driven by the AI technology.

Neurolov and mobiNODE Partner to Strengthen DePIN with AI-Powered Infrastructure

2025/09/18 07:15
blockchain3553516 main

Neurolov, a popular decentralized AI platform, has collaborated with mobiNODE, a NOWchain-powered protocol using Proof-of-Mobile consensus mechanism. The partnership is aimed at fortifying the decentralized physical infrastructure network (DePIN) by leveraging AI compute facilities. As mentioned in the official announcement shared by Neurolov on X, the development is set to broaden the adoption of $NLOV, its native token, within the NOWchain ecosystem. Additionally, the collaboration also merges community-led compute and the growth engine of mobiNODE.

Neurolov and mobiNODE Alliance Accelerates DePIN Infrastructure with at AI and Web3’s Intersection

As included in the partnership, the users can expect a robust DePIN infrastructure driven by the AI technology. Hence, both entities are endeavoring to expedite the AI and Web3’s convergence to fuel wider adoption via improved decentralization. In this respect, Neurolov delivers community-led compute capabilities while mobiNODE offers growth-centered ecosystem tools. This paves the way for optimized efficiency and scalability across diverse DePIN networks. Thu, the synergy is set to strengthen enterprises and users alike with enhanced engagement and trust within the decentralized sector.

Driving Transparency and Trust via Decentralized Innovation

According to Neurolov, the joint effort highlights the wider trend of combining decentralized infrastructure and AI to accelerate DePIN accessibility and scalability. Keeping this in view, the development reinforces decentralized innovation to boost trust, transparency, and resilience in the digital financial ecosystem. Ultimately, the duo focuses on broadening $NLOV’s utility at the intersection of Web3 and AI landscapes.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Novo Nordisk cuts cash prices for Wegovy, Ozempic

Novo Nordisk cuts cash prices for Wegovy, Ozempic

The post Novo Nordisk cuts cash prices for Wegovy, Ozempic appeared on BitcoinEthereumNews.com. Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to make the treatments more accessible.  The Danish drugmaker is lowering the price of the drugs for existing cash-paying patients to $349 per month from $499 per month. But Novo Nordisk said the cash-pay cost of the highest dose of Ozempic will remain $499 per month.  Also on Monday, Novo Nordisk launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment. After that period, people move to the new standard monthly direct-to-consumer price. The company’s introductory offer ends on March 31.  The announcements come days after President Donald Trump struck deals with Novo Nordisk and chief rival Eli Lilly to make their popular GLP-1 drugs easier for Americans to access and afford. Those agreements will involve cutting the prices the government pays for the drugs, introducing Medicare coverage of obesity drugs for the first time for certain patients and offering discounted medicines on the government’s new direct-to-consumer website launching in January called TrumpRx.  “Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay,” said Dave Moore, Novo Nordisk’s head of U.S. operations, said in a release. “It is part of a larger strategy to expand access that includes building relationships with telehealth providers and major retailers, expanding coverage, and working with the Administration to lower costs for people living with chronic diseases like…
Share
BitcoinEthereumNews2025/11/17 21:30